MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$3,040K
Net Income
-$49,013K
Net Profit Margin
-1612.27%
EPS
-$0.4
Unit: Thousand (K) dollars
Revenue Breakdown
Supply revenue
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
Revenue
3,040
21,459*
348
Research and development expenses
38,009
45,922*
30,971
Selling, general and administrative expenses
23,451
32,794*
24,520
Total operating expenses
61,460
78,716*
55,491
Operating loss
-58,420
-57,257*
-55,143
Interest income
5,650
7,453*
6,713
Fair value change - earnout
-
-998*
-
Fair value change - warrants
-5,942
-48,601*
23,792
Loss on disposal of property, plant and equipment
-
-
-1
Foreign exchange gains/(losses)
-1,613
12,401*
218
Gain before tax
-48,441
12,196
-72,005
Gain for the year
-48,441
12,196*
-72,005
Unrealized loss/(gain) on available-for-sale securities, net of tax
-572
-613*
313
Total comprehensive gain for the year, net of tax
-49,013
11,583
-71,692
Basic EPS
-0.4
0.098
-0.61
Diluted EPS
-0.4
0.098
-0.61
Basic Average Shares
121,716,006
117,848,196
119,000,266
Diluted Average Shares
121,716,006
117,848,196
119,000,266
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
gain for the year, net...
-$49,013K
Gain for the year
-$48,441K
Unrealized loss/(gain) on
available-for-sale securities, net...
-$572K
Gain before tax
-$48,441K
Fair value change -
warrants
-$5,942K
Interest income
$5,650K
Supply revenue
$3,040K
Operating loss
-$58,420K
Revenue
$3,040K
Foreign exchange
gains/(losses)
-$1,613K
Total operating
expenses
$61,460K
Research and development
expenses
$38,009K
Selling, general and
administrative expenses
$23,451K
Buy us a coffee
NewAmsterdam Pharma Co N.V. (NAMSW)
NewAmsterdam Pharma Co N.V. (NAMSW)